Is Q32 Bio Inc. (QTTB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 31.3% / 30% | 129.0% / 30% | 0.9% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 31.3% / 33% | 129.0% / 33% | 0.9% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 20.5% / 33% | 84.4% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 31.3% / 33% | 129.0% / 33% | 0.9% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 20.5% / 33% | 84.4% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 64.4% | |
| Operating Margin | 85.4% | |
| Net Margin | 55.5% | |
| Return on Equity (ROE) | 125.1% | |
| Return on Assets (ROA) | 13.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$34M |
| Free Cash Flow | -$34M |
| Total Debt | $15M |
| Debt-to-Equity | 36.5 |
| Current Ratio | 4.9 |
| Total Assets | $62M |
Price & Trading
| Last Close | $7.14 |
| 50-Day MA | $4.92 |
| 200-Day MA | $3.01 |
| Avg Volume | 196K |
|
52-Week Range
$1.34
| |
About Q32 Bio Inc. (QTTB)
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Q32 Bio Inc. (QTTB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Q32 Bio Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Q32 Bio Inc.'s debt ratio?
Q32 Bio Inc.'s debt ratio is 31.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 20.5%.
What are Q32 Bio Inc.'s key financial metrics?
Q32 Bio Inc. has a market capitalization of $106M, trailing P/E ratio of 3.0, and revenue of $54M. The company maintains a gross margin of 64.4% and a net margin of 55.5%. Return on equity stands at 125.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.